Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium

被引:13
作者
Beyer, Katharina [1 ]
Leenen, Renee [1 ]
Venderbos, Lionne D. F. [1 ]
Helleman, Jozien [1 ]
Denijs, Frederique [1 ]
Bramer, Wichor [2 ]
Vasilyeva, Vera [3 ]
Briers, Erik [4 ]
Rivas, Juan Gomez [5 ]
Chloupkova, Renata [6 ,7 ]
Majek, Ondrej [6 ,7 ]
Annemans, Lieven [8 ]
Vynckier, Pieter [8 ]
Basu, Partha [9 ]
Chandran, Arunah [9 ]
van den Bergh, Roderick [1 ]
Collen, Sarah [3 ]
van Poppel, Hendrik [3 ]
Roobol, Monique J. [1 ]
机构
[1] Univ Med Ctr Rotterdam, Erasmus MC Canc Inst, Dept Urol, NL-3015 GD Rotterdam, Netherlands
[2] Univ Med Ctr Rotterdam, Med Lib, Erasmus MC, NL-3015 GD Rotterdam, Netherlands
[3] European Assoc Urol, Policy Off, NL-6842 CV Arnhem, Netherlands
[4] Europa Uomo, B-2018 Antwerp, Belgium
[5] Clin San Carlos Univ Hosp, Dept Urol, Madrid 28040, Spain
[6] Inst Hlth Informat & Stat Czech Republ, Natl Screening Ctr, Prague 12801, Czech Republic
[7] Masaryk Univ, Inst Biostat & Anal, Fac Med, Brno 62500, Czech Republic
[8] Gasthuisberg Univ Hosp, Katholieke Univ Leuven, Dept Urol, B-3000 Leuven, Belgium
[9] World Hlth Org, Int Agcy Res Canc, F-69366 Lyon, France
关键词
prostate cancer; screening; early detection; policy; health policy; ANTIGEN; RATES;
D O I
10.3390/jpm14010084
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
With the new policy recommendation in 2022 to explore the possibilities of screening for prostate cancer by the European Commission, the landscape for prostate cancer early detection is evolving. In line with this recommendation, the PRAISE-U project aims to evaluate the early detection and diagnosis of prostate cancer through customised and risk-based screening programmes, with the goal to align protocols across European Union member states. This systematic review is part of the PRAISE-U project, with the goal to review the policy, medical guideline recommendations, and the current level of opportunistic screening presented in the scientific literature on prostate cancer early detection from 2016 to 2023 in European Union member states. An extensive literature search was performed on 1 June 2023 in a large number of databases, including Embase.com, Medline (Ovid), Web of Science Core Collection, Google Scholar, and Policy Commons. We identified 318 articles (qualitative, quantitative, and reviews), of which 41 were included in the full-text screening. Seventeen articles were ultimately identified as eligible for inclusion. The included articles revealed significant variations towards PSA-based early detection policies for prostate cancer in nine European countries. Despite official recommendations, opportunistic screening was prevalent across all nine countries regardless of recommendations for or against PSA-based early detection. This systematic review suggests that the current early detection policies are not fit for purpose. High levels of opportunistic screening and overdiagnosis persist, prompting policy recommendations for standardised guidelines, informed decision making, and increased awareness to improve efficiency and effectiveness in early detection.
引用
收藏
页数:12
相关论文
共 34 条
[1]   Quality management in (prostate) cancer care: what do European cancer control plans tell us? [J].
Albreht, Tit .
WORLD JOURNAL OF UROLOGY, 2021, 39 (01) :37-39
[2]   De-duplication of database search results for systematic reviews in EndNote [J].
Bramer, Wichor M. ;
Giustini, Dean ;
de Jonge, Gerdien B. ;
Holland, Leslie ;
Bekhuis, Tanja .
JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION, 2016, 104 (03) :240-243
[3]  
Bratt Ola, 2023, BMJ Oncol, V2, pe000039, DOI 10.1136/bmjonc-2023-000039
[4]   History of the discovery and clinical translation of prostate-specific antigen [J].
Catalona, William J. .
ASIAN JOURNAL OF UROLOGY, 2014, 1 (01) :12-14
[5]  
Conde M.G., 2019, BMJ Evid. Based Med, V24, pA53, DOI [10.1136/bmjebm-2019-POD.107, DOI 10.1136/BMJEBM-2019-POD.107]
[6]   Uptake of cancer screening services among middle and older ages in Ireland: the role of healthcare eligibility [J].
Connolly, S. ;
Whyte, R. .
PUBLIC HEALTH, 2019, 173 :42-47
[7]  
Consortium P-U, 2023, PRAISE-U Consortium
[8]  
De Angelis Gabriela, 2007, Rev Urol, V9, P113
[9]   A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer [J].
Hugosson, Jonas ;
Roobol, Monique J. ;
Mansson, Marianne ;
Tammela, Teuvo L. J. ;
Zappa, Marco ;
Nelen, Vera ;
Kwiatkowski, Maciej ;
Lujan, Marcos ;
Carlsson, Sigrid, V ;
Talala, Kirsi M. ;
Lilja, Hans ;
Denis, Louis J. ;
Recker, Franz ;
Paez, Alvaro ;
Puliti, Donella ;
Villers, Arnauld ;
Rebillard, Xavier ;
Kilpelainen, Tuomas P. ;
Stenman, Ulf H. ;
Godtman, Rebecka Arnsrud ;
Kollberg, Karin Stinesen ;
Moss, Sue M. ;
Kujala, Paula ;
Taari, Kimmo ;
Huber, Andreas ;
van der Kwast, Theodorus ;
Heijnsdijk, Eveline A. ;
Bangma, Chris ;
De Koning, Harry J. ;
Schroder, Fritz H. ;
Auvinen, Anssi .
EUROPEAN UROLOGY, 2019, 76 (01) :43-51
[10]  
Institut National Du Cancer, 2022, 20212030 FRANCE Ten-Year Cancer-Control Strategy 20212025 Roadmap